2025-06878NoticeWallet

NIH Grants Exclusive License for Brain-Targeting Nano-Drug Tech Platform

Published Date: 4/22/2025

Notice

Summary

The National Cancer Institute plans to give Sangam Lifesciences an exclusive license to use a new drug delivery technology that targets the brain and lymphatic system based on molecule size. This could speed up better treatments for diseases affecting these areas. Interested parties must send comments or license requests by April 22, 2025, or miss out on this opportunity.

Analyzed Economic Effects

4 provisions identified: 1 benefits, 3 costs, 0 mixed.

Exclusive License Contemplated for Sangam

The National Cancer Institute is contemplating granting Sangam Lifesciences, Inc. an exclusive patent license to practice the listed inventions. The prospective exclusive license territory may be worldwide and would be royalty-bearing and limited to development, manufacture, and commercialization of a poly (L-lysine succinylated) (PLS) alpha-galactosylceramide prodrug for human and veterinary uses in the treatment of cancer.

Exclusivity Limited to Cancer Use

The scope of exclusivity, if granted, will be limited to the PLS-alpha-galactosylceramide prodrug for the treatment of cancers. The notice explicitly states that other fields of use would remain available, including use of the PLS prodrug for non-oncology indications and PLS conjugated to other therapeutic agents.

Application Confidentiality and Objection Rules

Complete license applications filed in response to this notice will be treated as objections to the grant and are presumed to contain business confidential information. Comments or objections that are not in the form of a license application will not be treated confidentially and may be made publicly available; license application materials will be released only as required under the Freedom of Information Act (5 U.S.C. 552).

April 22, 2025 Application Deadline

Only written comments and/or license applications received by the National Cancer Institute's Technology Transfer Center on or before April 22, 2025 will be considered. Interested parties who do not submit by that date may not be able to file timely objections or license applications in response to this notice.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Published Date
4/22/2025

Department and Agencies

Department
Independent Agency
Agency
Health and Human Services Department
National Institutes of Health
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register